- NeoGenomics (NASDAQ:NEO) signs an agreement with Thermo Fisher Scientific (TMO) to join the Next-Generation Sequencing Companion Dx Center of Excellence Program. NeoGenomics is one of the first laboratories to offer the newly FDA-approved Oncomine Dx Target Test for Non-Small Cell Lung Cancer (NSCLC). This methodology allows rapid analysis of samples compared to previously approved testing approaches.
- NeoGenomics' Pharma Services Division supported the analytical validation of the Oncomine Dx Target Test for submission to the FDA. The test evaluates 23 genes associated with NSCLC.